Ahead of its annual meeting, Dr. Martens plc issued a performance update confirming that trading since April has been in line with expectations, leaving its full-year guidance for fiscal 2027 unchanged. The performance continues to be led by wholesale strength in the U.S.
Dr. Martens said in its brief update, “Our largest market, the USA, continues to grow, with wholesale particularly encouraging. Our largest Asian markets, Japan and South Korea, are both performing well. Our European markets are performing as expected against a challenging consumer backdrop.”
The UK-based footwear brand also said it’s on track with its strategic objectives for FY27, as shared when it reported results for the fiscal year ended March 29 on May 19.
The company’s objectives are:
- Consumer: Drive full price revenue mix in the UK and DACH
- Product: Successfully introduce an “innovative new sandals range”
- Markets: Launch new retail concepts in key cities globally
- Organization: Unlock operating model and technology benefits
Image courtesy Dr. Martens
